Scienture Holdings, Inc.

corporate_fare Company Profile

Scienture Holdings, Inc.

SCNX·NASDAQ·Life Sciences·CIK 0001382574

Scienture Holdings, Inc. is a pharmaceutical company that develops and sells products for central nervous system and cardiovascular diseases in the United States. The company is developing SCN-102, an oral liquid formulation of losartan potassium, which is currently in Phase 1 trials. SCN-102 is intended to treat hypertension, diabetic nephropathy, and reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy. Scienture Holdings also develops SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. Additionally, the company is working on SCN-106, a thrombolytic agent designed to bind to fibrin in clots and convert entrapped plasminogen to plasmin. Another product in development is SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional pain relief. Scienture Holdings, Inc. is headquartered in Commack, New York.

Scienture Holdings, Inc. (NASDAQ:SCNX) is a publicly traded company in the Life Sciences sector. Wiseek monitors SCNX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

Scienture's Arbli™ Drug Gains 12.5 Million New Covered Lives, Boosting Commercial Access (2026-06-18)
REZENOPY™ Secures Major Health Plan Coverage, Expanding Access to 100M+ Lives Ahead of July Launch (2026-06-09)
Scienture Secures Key Patent for REZENOPY™ Naloxone Spray, Extending IP Protection Through 2041 (2026-06-02)
CFO Resigns Amidst Financial Distress; Co-CEO Appointed Interim CFO (2026-05-29)
Scienture Reports Q1 Revenue Surge, Patent Wins, and REZENOPY™ Market Expansion (2026-05-22)

Financial Snapshot

Fiscal year ended December 31, 2025

Revenue

$431.61K

Net Income

-$41.51M

Diluted EPS

-$2.70

Op. Cash Flow

-$13.38M

Gross Profit

$331.48K

Operating Income

-$42.59M

Cash & Equivalents

$6.66M

Debt / Equity

0.00×

Net Margin

-96.18×

Shares Outstanding

40.63M sh

Source: 10-K · filed 2026-04-30 · accession 0001493152-26-020707

Browse all tickers starting with S →

show_chartPrice Chart

Loading chart...

feed SCNX - Latest Insights

Filing Type

Date Range

SCNX

Jun 18, 2026, 8:05 AM EDT

Source: GlobeNewswire

Importance Score:

Scienture's Arbli™ Drug Gains 12.5 Million New Covered Lives, Boosting Commercial Access

Price at Filing: $0.385

Real-time Price: $0.3814

Change: -$0.0036 (-0.94%)

Market Cap: $15.497M

Sentiment: Positive

View Wiseek Article

SCNX

Jun 09, 2026, 8:05 AM EDT

Source: GlobeNewswire

Importance Score:

REZENOPY™ Secures Major Health Plan Coverage, Expanding Access to 100M+ Lives Ahead of July Launch

Price at Filing: $0.3774

Real-time Price: $0.3814

Change: +$0.0040 (+1%)

Market Cap: $15.497M

Sentiment: Positive

View Wiseek Article

SCNX

Jun 02, 2026, 8:05 AM EDT

Source: GlobeNewswire

Importance Score:

Scienture Secures Key Patent for REZENOPY™ Naloxone Spray, Extending IP Protection Through 2041

Price at Filing: $0.3963

Real-time Price: $0.3814

Change: -$0.0149 (-4%)

Market Cap: $15.497M

Sentiment: Positive

View Wiseek Article

SCNX

May 29, 2026, 5:00 PM EDT

Filing Type: 8-K

Importance Score:

CFO Resigns Amidst Financial Distress; Co-CEO Appointed Interim CFO

Price at Filing: $0.413

Real-time Price: $0.3814

Change: -$0.0316 (-8%)

Market Cap: $15.497M

Sentiment: Negative

View Wiseek Article

SCNX

May 22, 2026, 5:00 PM EDT

Filing Type: 8-K

Importance Score:

Scienture Reports Q1 Revenue Surge, Patent Wins, and REZENOPY™ Market Expansion

Price at Filing: $0.395

Real-time Price: $0.3814

Change: -$0.0136 (-3%)

Market Cap: $15.497M

Sentiment: Neutral

View Wiseek Article

SCNX

May 18, 2026, 8:38 AM EDT

Source: GlobeNewswire

Importance Score:

Scienture Secures $11M Non-Dilutive Debt, Boosting Capital Amid Q1 Revenue Surge and Margin Expansion

Price at Filing: $0.4097

Real-time Price: $0.3814

Change: -$0.0283 (-7%)

Market Cap: $15.497M

Sentiment: Positive

View Wiseek Article

SCNX

May 15, 2026, 4:38 PM EDT

Source: Wiseek News

Importance Score:

SCNX Q1 Revenue Soars 449%, EPS Loss Narrows to $0.08, Beating Estimates

Price at Filing: $0.403

Real-time Price: $0.3814

Change: -$0.0216 (-5%)

Market Cap: $15.497M

Sentiment: Positive

View Wiseek Article

SCNX

May 15, 2026, 4:31 PM EDT

Filing Type: 10-Q

Importance Score:

Scienture Holdings Reports Q1 Loss, Discloses Going Concern, Secures $11M High-Interest Debt

Price at Filing: $0.3983

Real-time Price: $0.3814

Change: -$0.0169 (-4%)

Market Cap: $15.497M

Sentiment: Negative

View Wiseek Article

SCNX

May 12, 2026, 7:00 AM EDT

Source: Wiseek News

Importance Score:

SCNX Q4 Revenue Estimate Hits Zero, Signaling Severe Financial Distress

Price at Filing: $0.4175

Real-time Price: $0.3814

Change: -$0.0361 (-9%)

Market Cap: $15.497M

Sentiment: Negative

View Wiseek Article

SCNX

May 08, 2026, 4:36 PM EDT

Source: Reuters

Importance Score:

SCNX Expected to Report Q1 Loss of 22 Cents Per Share, Signaling Continued Financial Pressure

Price at Filing: $0.400

Real-time Price: $0.3814

Change: -$0.0186 (-5%)

Market Cap: $15.497M

Sentiment: Negative

View Wiseek Article

SCNX

May 06, 2026, 8:05 AM EDT

Source: GlobeNewswire

Importance Score:

Scienture Secures Third Patent for ARBLI™ Oral Suspension, Extending Market Exclusivity to 2041

Price at Filing: $0.4069

Real-time Price: $0.3814

Change: -$0.0255 (-6%)

Market Cap: $15.497M

Sentiment: Positive

View Wiseek Article

SCNX

May 05, 2026, 5:00 PM EDT

Filing Type: 8-K

Importance Score:

Scienture Holdings Files Investor Presentation with Material Discrepancy Regarding Recent Debt Financing

Price at Filing: $0.3906

Real-time Price: $0.3814

Change: -$0.0092 (-2%)

Market Cap: $15.497M

Sentiment: Negative

View Wiseek Article

SCNX

May 01, 2026, 5:25 PM EDT

Filing Type: 8-K

Importance Score:

Secures $11M in Highly Restrictive Debt Financing with Extensive Collateral and Punitive Default Terms

Price at Filing: $0.4012

Real-time Price: $0.3814

Change: -$0.0198 (-5%)

Market Cap: $15.497M

Sentiment: Negative

View Wiseek Article

SCNX

Apr 30, 2026, 5:00 PM EDT

Filing Type: 10-K/A

Importance Score:

Amended 10-K Reveals Widespread Insider Trading Reporting Failures Among Executives and Directors

Price at Filing: $0.400

Real-time Price: $0.3814

Change: -$0.0186 (-5%)

Market Cap: $15.497M

Sentiment: Negative

View Wiseek Article

SCNX

Apr 15, 2026, 8:05 AM EDT

Source: GlobeNewswire

Importance Score:

Nasdaq Grants Scienture 180-Day Extension to Regain Bid Price Compliance

Price at Filing: $0.340

Real-time Price: $0.3814

Change: +$0.0414 (+12%)

Market Cap: $15.497M

Sentiment: Neutral

View Wiseek Article

SCNX

Mar 30, 2026, 8:09 AM EDT

Source: Dow Jones Newswires

Importance Score:

Massive $2.70/Share Loss Reported by Scienture Holdings for 2025

Price at Filing: $0.4191

Real-time Price: $0.3814

Change: -$0.0377 (-9%)

Market Cap: $15.497M

Sentiment: Negative

View Wiseek Article

SCNX

Mar 30, 2026, 8:05 AM EDT

Filing Type: 10-K

Importance Score:

Scienture Holdings Reports Massive $41.5M Net Loss, Significant Impairment, and Going Concern Warning

Price at Filing: $0.420

Real-time Price: $0.3814

Change: -$0.0386 (-9%)

Market Cap: $15.497M

Sentiment: Negative

View Wiseek Article

SCNX

Mar 11, 2026, 8:05 AM EDT

Source: GlobeNewswire

Importance Score:

REZENOPY™ Naloxone Spray Secures GPO Access to 60% of U.S. Institutional Market

Price at Filing: $0.484

Real-time Price: $0.3814

Change: -$0.1026 (-21%)

Market Cap: $15.497M

Sentiment: Positive

View Wiseek Article

corporate_fare Company Profile